214 related articles for article (PubMed ID: 23776197)
1. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.
Leandro-García LJ; Inglada-Pérez L; Pita G; Hjerpe E; Leskelä S; Jara C; Mielgo X; González-Neira A; Robledo M; Avall-Lundqvist E; Gréen H; Rodríguez-Antona C
J Med Genet; 2013 Sep; 50(9):599-605. PubMed ID: 23776197
[TBL] [Abstract][Full Text] [Related]
2. Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
Abe Y; Taira N; Kashiwabara K; Tsurutani J; Kitada M; Takahashi M; Kato H; Kikawa Y; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Takashima T; Aihara T; Mukai H; Hara F; Shien T; Doihara H; Toyooka S
Acta Med Okayama; 2022 Dec; 76(6):661-671. PubMed ID: 36549768
[TBL] [Abstract][Full Text] [Related]
3. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
Baldwin RM; Owzar K; Zembutsu H; Chhibber A; Kubo M; Jiang C; Watson D; Eclov RJ; Mefford J; McLeod HL; Friedman PN; Hudis CA; Winer EP; Jorgenson EM; Witte JS; Shulman LN; Nakamura Y; Ratain MJ; Kroetz DL
Clin Cancer Res; 2012 Sep; 18(18):5099-109. PubMed ID: 22843789
[TBL] [Abstract][Full Text] [Related]
4. Targeted Sequencing Reveals Low-Frequency Variants in
Apellániz-Ruiz M; Tejero H; Inglada-Pérez L; Sánchez-Barroso L; Gutiérrez-Gutiérrez G; Calvo I; Castelo B; Redondo A; García-Donás J; Romero-Laorden N; Sereno M; Merino M; Currás-Freixes M; Montero-Conde C; Mancikova V; Åvall-Lundqvist E; Green H; Al-Shahrour F; Cascón A; Robledo M; Rodríguez-Antona C
Clin Cancer Res; 2017 Mar; 23(5):1227-1235. PubMed ID: 27582484
[No Abstract] [Full Text] [Related]
5. Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
Marcath LA; Kidwell KM; Vangipuram K; Gersch CL; Rae JM; Burness ML; Griggs JJ; Van Poznak C; Hayes DF; Smith EML; Henry NL; Beutler AS; Hertz DL
Br J Clin Pharmacol; 2020 May; 86(5):880-890. PubMed ID: 31823378
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
7. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
Lam SW; Frederiks CN; van der Straaten T; Honkoop AH; Guchelaar HJ; Boven E
Br J Cancer; 2016 Nov; 115(11):1335-1342. PubMed ID: 27736846
[TBL] [Abstract][Full Text] [Related]
8. Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
Chua KC; Xiong C; Ho C; Mushiroda T; Jiang C; Mulkey F; Lai D; Schneider BP; Rashkin SR; Witte JS; Friedman PN; Ratain MJ; McLeod HL; Rugo HS; Shulman LN; Kubo M; Owzar K; Kroetz DL
Clin Pharmacol Ther; 2020 Sep; 108(3):625-634. PubMed ID: 32562552
[TBL] [Abstract][Full Text] [Related]
9. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Guijosa A; Freyria A; Espinosa-Fernandez JR; Estrada-Mena FJ; Armenta-Quiroga AS; Ortega-Treviño MF; Catalán R; Antonio-Aguirre B; Villarreal-Garza C; Perez-Ortiz AC
Clin Transl Sci; 2022 Oct; 15(10):2403-2436. PubMed ID: 35892315
[TBL] [Abstract][Full Text] [Related]
11. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
Wheeler HE; Gamazon ER; Wing C; Njiaju UO; Njoku C; Baldwin RM; Owzar K; Jiang C; Watson D; Shterev I; Kubo M; Zembutsu H; Winer EP; Hudis CA; Shulman LN; Nakamura Y; Ratain MJ; Kroetz DL; ; Cox NJ; Dolan ME
Clin Cancer Res; 2013 Jan; 19(2):491-9. PubMed ID: 23204130
[TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.
Terrazzino S; Argyriou AA; Cargnin S; Antonacopoulou AG; Briani C; Bruna J; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP; Canonico PL; Genazzani AA; Cavaletti G
J Peripher Nerv Syst; 2015 Mar; 20(1):15-23. PubMed ID: 25858589
[TBL] [Abstract][Full Text] [Related]
13. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
Hertz DL; Roy S; Jack J; Motsinger-Reif AA; Drobish A; Clark LS; Carey LA; Dees EC; McLeod HL
Breast Cancer Res Treat; 2014 May; 145(1):245-54. PubMed ID: 24706167
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients.
Won HH; Lee J; Park JO; Park YS; Lim HY; Kang WK; Kim JW; Lee SY; Park SH
Cancer; 2012 Jun; 118(11):2828-36. PubMed ID: 22020760
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy.
Komatsu M; Wheeler HE; Chung S; Low SK; Wing C; Delaney SM; Gorsic LK; Takahashi A; Kubo M; Kroetz DL; Zhang W; Nakamura Y; Dolan ME
Clin Cancer Res; 2015 Oct; 21(19):4337-46. PubMed ID: 26015512
[TBL] [Abstract][Full Text] [Related]
16. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.
Apellániz-Ruiz M; Lee MY; Sánchez-Barroso L; Gutiérrez-Gutiérrez G; Calvo I; García-Estévez L; Sereno M; García-Donás J; Castelo B; Guerra E; Leandro-García LJ; Cascón A; Johansson I; Robledo M; Ingelman-Sundberg M; Rodríguez-Antona C
Clin Cancer Res; 2015 Jan; 21(2):322-8. PubMed ID: 25398452
[TBL] [Abstract][Full Text] [Related]
18. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
Mahmoudpour SH; Bandapalli OR; da Silva Filho MI; Campo C; Hemminki K; Goldschmidt H; Merz M; Försti A
BMC Cancer; 2018 Aug; 18(1):820. PubMed ID: 30111286
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies.
Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Kalofonos HP; Chroni E
J Neurol; 2005 Dec; 252(12):1459-64. PubMed ID: 16284715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
